This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2001 Remove Biophysical Assays Remove Pharmaceuticals Related Topics
Screening Hits Compound Screening Fragment Screening Biochemical Assays Computational Chemistry Assay Development Protein Production Small Molecule Drug Development Trials More Related Topics >
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

NOVEMBER 1, 2023

Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca. In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets.

Fragment Screening 96
Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024